Your patients are asking about retatrutide. Some of them have already bought it.
Search interest in retatrutide has climbed steadily for the past year, and it now draws several hundred thousand searches a month in the United States alone — more than most approved medications. A large share of those searches are people asking where to buy it and how much to take. Almost none of them are asking a clinician first.
That is the position this drug puts you in. Retatrutide is not approved, not prescribable, and not available through any legitimate pharmacy channel — and yet it is one of the most-searched compounds in metabolic medicine. This guide covers what it actually is, where it stands with the FDA, how it differs from cagrilintide, and what to say when a patient tells you they have already started.
What is retatrutide?
Retatrutide is an investigational injectable peptide developed by Eli Lilly. It is a triple agonist: it activates the GLP-1 receptor, the GIP receptor, and the glucagon receptor.
That third target is what separates it from the drugs already on the market. Semaglutide is a single agonist at GLP-1. Tirzepatide is a dual agonist at GLP-1 and GIP. Retatrutide adds glucagon-receptor activity, which is counterintuitive to anyone who remembers glucagon purely as the hormone that raises blood glucose. In this context, glucagon-receptor agonism is being pursued for its effect on energy expenditure and hepatic fat, working against a background of GLP-1-mediated appetite suppression and improved insulin response.
So yes, retatrutide is a peptide. It is a synthetic peptide analog, in the same broad structural family as semaglutide and tirzepatide, and it is administered as a weekly subcutaneous injection in trials.
What the Phase 3 data shows
Lilly has reported results from its Phase 3 TRIUMPH program and from TRANSCEND-T2D-1. The weight-reduction figures reported across those trials are substantial — in the range of roughly 21% to 29% mean weight change depending on the trial and duration, with the largest reported at 80 weeks.
Those are headline numbers, and they deserve two pieces of context before you repeat them to a patient. First, trial populations are selected, supported, and monitored in ways your clinic cannot replicate. Second, a mean is not a promise; the distribution around it matters, and so does what happens after discontinuation, which is the part of the GLP-1 story practices are only now learning to manage.
Is retatrutide FDA approved?
No. As of this writing, retatrutide is an investigational drug. It has not been approved by the FDA for any indication.
Lilly has indicated it intends to submit a Biologics License Application in the first quarter of 2027. An FDA decision would follow that submission, which puts any realistic approval window at late 2027 or into 2028 — and that assumes the submission goes smoothly, which is never a given.
The practical consequence is simple and worth stating plainly to patients: there is no legitimate way to obtain retatrutide outside a clinical trial. It is not available by prescription. It is not available from a 503A compounding pharmacy. A compounding pharmacy may only compound from an approved drug or from a bulk substance that appears on the FDA’s 503A bulks list, and retatrutide is neither.
Then where is everyone getting it?
From research-chemical suppliers. The websites selling retatrutide are not pharmacies; they typically sell vials labeled “for research use only, not for human consumption,” which is the disclaimer that lets them ship an unapproved drug without a prescription.
What that label means in practice is that nobody has verified what is in the vial. There is no assurance of identity, purity, sterility, endotoxin load, or accurate quantity. Certificates of Analysis supplied by these sellers are frequently produced by the seller, not by an independent laboratory, and a COA that is not tied to the specific lot in front of you tells you nothing at all.
This is the single most useful thing you can explain to a patient who is already using it: the risk is not only the drug, it is that they do not know what they injected.
Where cagrilintide fits
Cagrilintide is a different mechanism entirely, and it is worth understanding separately because it is frequently mentioned in the same breath.
Cagrilintide is a long-acting amylin analog, developed by Novo Nordisk. Amylin is co-secreted with insulin from pancreatic beta cells and contributes to satiety, gastric emptying, and post-meal glucagon suppression. It is a distinct satiety pathway from the incretin system, which is why combining the two is attractive: cagrilintide has been developed alongside semaglutide as a fixed combination, and that combination has been the subject of its own trial program and regulatory filings.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Medical Weight Loss & Metabolic Health courses — live patients, expert faculty, and ongoing mentorship.
Cagrilintide as a standalone agent is also not FDA approved. The same sourcing warning applies, and it is sold on the same research-chemical sites.
What to say when a patient tells you they are already on it
Lecturing rarely works, and refusing to engage guarantees they will simply stop telling you. A more productive sequence:
- Document it. Whatever they are taking belongs in the chart, including the source, the labeled concentration, and what they believe the dose to be. You cannot manage what is not recorded.
- Explain the identity problem, not just the legal one. “It is not approved” sounds like bureaucracy. “Nobody has verified what is in that vial” is the argument that actually lands.
- Screen for what you would screen for with any incretin therapy — personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis history, gallbladder disease, gastroparesis, and pregnancy status.
- Watch nutrition and lean mass. Rapid weight reduction at these magnitudes carries a real risk of lean-mass loss and inadequate protein intake, and this is where a clinician adds value regardless of the source of the drug.
- Offer the approved alternative. Patients frequently reach for the gray market because they were never offered a supervised path. Semaglutide and tirzepatide are approved, prescribable, and supported by durable evidence.
We are not going to publish reconstitution volumes or dosing for retatrutide, and you should be suspicious of any site that does. There is no established human dosing outside of a controlled trial, and the pages offering that information are almost always the same pages selling the vial.
Why this matters for your practice
The gray market for metabolic peptides exists because demand outran the supervised supply. Patients who cannot access, afford, or tolerate the approved options go looking, and they find sellers who ask no questions.
The practices that handle this well are not the ones that dismiss it. They are the ones whose clinicians can explain the mechanism, the evidence, and the sourcing risk in language a patient believes, and who can then offer a supervised alternative. That requires actually understanding the incretin class, the amylin pathway, the regulatory framework governing compounded peptides, and the monitoring that keeps a metabolic program safe.
Frequently asked questions
Is retatrutide a GLP-1?
It acts on the GLP-1 receptor, but calling it “a GLP-1” understates it. It is a triple agonist at the GLP-1, GIP, and glucagon receptors. Semaglutide is the single-agonist comparison; tirzepatide is the dual.
Is retatrutide a peptide?
Yes. It is a synthetic peptide analog given by weekly subcutaneous injection in trials.
What does retatrutide do?
In trials it produces substantial weight reduction, reported in the range of roughly 21% to 29% mean weight change depending on the trial and duration, alongside metabolic effects attributed to its combined receptor activity.
Is retatrutide safe?
Its safety profile is still being characterized in Phase 3 trials, which is precisely why it is not yet approved. Separately, material bought from research-chemical suppliers carries risks that have nothing to do with the molecule — unverified identity, purity, and sterility.
When will retatrutide be FDA approved?
Lilly has signaled a regulatory submission in the first quarter of 2027, which places a possible decision in late 2027 or 2028. No approval date is guaranteed.
Can a compounding pharmacy make retatrutide?
No. Compounding requires either an approved drug or a bulk substance on the FDA’s 503A bulks list. Retatrutide is neither, so no legitimate 503A pharmacy can supply it.
Is cagrilintide the same thing?
No. Cagrilintide is an amylin analog and works through a different satiety pathway. It is also investigational and not FDA approved as a standalone agent.
Is retatrutide available yet?
No. Retatrutide is investigational and in Phase 3 trials. Lilly has signalled a regulatory submission in the first quarter of 2027, which puts a possible FDA decision in late 2027 or 2028. It is not available by prescription, and because it is neither an approved drug nor on the 503A bulks list, no legitimate compounding pharmacy can supply it either. The only lawful access today is enrolment in a clinical trial.
Train for the conversation you are already having
Empire’s Advanced Weight Management Certification covers the incretin class in clinical depth — mechanism, patient selection, titration, adverse-effect management, lean-mass preservation, and what happens at discontinuation — so you can run a supervised metabolic program rather than manage the aftermath of an unsupervised one.
For the wider peptide category and the regulatory framework behind compounded peptides, see the Empire Peptide Therapy Certification, which covers 503A and 503B compounding, sourcing and Certificates of Analysis, and where each named agent currently stands with the FDA.
Deeper clinical references: the retatrutide clinical overview and the cagrilintide overview in the Peptide Therapy Resource Center. Related reading: peptide injections for weight loss and GLP-1 weight loss training.
